Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Oral Bosentan in Pulmonary Arterial Hypertension Class II

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* PAH NYHA Class II~* Significant elevation of mean pulmonary arterial pressure~* Significant elevation of pulmonary vascular resistance at rest~* Limited 6-minute walk distance~Exclusion Criteria:~* PAH secondary to portal hypertension, complex congenital heart disease or reverse shunt~* Restrictive or obstructive lung disease~* Significant vasoreactivity~* Treatments for PAH (within 4 weeks of randomization)

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): 62.5 mg table twice a day for 4 weeks followed by 125 mg tablet twice a day for 6 months followed by an open label period until end of study.
- 2 (Type: PLACEBO_COMPARATOR): placebo for 6 months followed by an open label period

Based on this trial design, predict the completion outcome and termination type (if applicable).